Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 2/20 | 0.48 |
| ▸ | FYN | P06241 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | DRD3 | P35462 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3041826 | 0.87 | ADRA1A (0.56) | ADRA1AFYNDRD2DRD3CA1 | |
| Hydrochloric Acid SCHEMBL1788805 | 0.85 | ADRA1A (0.54) | ADRA1AFYNDRD2DRD3CA1 | |
| SCHEMBL17014922 | 0.82 | CYP3A4 (0.43) | CA1CA2CYP3A4MAPTALDH1A1 | |
| SCHEMBL4388677 | 0.80 | FYN (0.56) | ADRA1AFYNDRD2DRD3CA1 | |
| SCHEMBL16816267 | 0.78 | ADRA1A (0.47) | ADRA1AFYNDRD2DRD3CA1 | |
| SCHEMBL17014945 | 0.77 | MEN1 (0.41) | CA1CA2CYP3A4MAPTALDH1A1 | |
| SCHEMBL22953307 | 0.76 | MAPT (0.71) | DRD2DRD3CYP3A4MAPTALDH1A1 | |
| SCHEMBL12595457 | 0.76 | MAPT (0.71) | DRD2DRD3CYP3A4MAPTALDH1A1 | |
| SCHEMBL7339771 | 0.74 | DRD2 (0.62) | ADRA1ADRD2DRD3MAPTALDH1A1 | |
| SCHEMBL8765937 | 0.74 | DRD2 (0.62) | ADRA1ADRD2DRD3MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | claimed |
| EP-4618980-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | Freedom Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| WO-2024107445-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES, INC. (US) | 2024-05-23 | — | — | WO | claimed |
| CN-112270066-B | Optimization method for calculating rigid coupling coefficient of satellite and computer equipment | 航天科工空间工程发展有限公司 | 2022-04-19 | — | — | CN | claimed |
| WO-2007069925-A2 | NON-NEUROTOXIC RECREATIONAL DRUGS AND A METHOD OF TREATING RECREATIONAL DRUG ABUSE | STARGATE INTERNATIONAL LIMITED (NZ) | 2007-06-21 | — | — | WO | claimed |
| WO-2026107229-A1 | REDUCING THE ADDICTIVE LIABILITY OF OPIOID ANALGESICS BY CO- ADMINISTERING 5HT2 RECEPTOR AGONISTS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2026-05-21 | — | — | WO | disclosed |
| WO-2026099114-A1 | POWER SUPPLY SYSTEM WITH HETEROGENEOUS POWER SUPPLIES FOR AUTOMATIC PARALLEL OPERATION | PHOENIX CONTACT GMBH & CO. KG (DE) | 2026-05-15 | — | — | WO | disclosed |
| US-20260135486-A1 | RIPPLE SUPPRESSION IN MULTI-PHASE BUCK CONVERTERS | MAXLINEAR, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4713342-A2 | SYSTEMS AND METHODS FOR REGULATING TARGET GENES | Epicrispr Biotechnologies, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20260049109-A1 | NOVEL IMMUNOMODULATORY, NEUROMODULATORY, OSTEOGENIC, AND ANTI-OSTEOPOROTIC HKUOT-S2 PROTEIN THAT ENHANCES BONE FRACTURE REPAIRS AND SUPPRESSES OSTEOPOROSIS DEVELOPMENT | UNIV HONG KONG (HK) | 2026-02-19 | — | — | US | disclosed |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | disclosed |
| EP-4618980-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | Freedom Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-20110224263-A1 | Cyclic pyridyl-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2011-09-15 | — | — | US | disclosed |
| WO-2009080223-A1 | CYCLIC PYRIDYL-N-(1,3,4)-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2009-07-02 | — | — | WO | disclosed |
| WO-2007069925-A2 | NON-NEUROTOXIC RECREATIONAL DRUGS AND A METHOD OF TREATING RECREATIONAL DRUG ABUSE | STARGATE INTERNATIONAL LIMITED (NZ) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007069925-A2 | NON-NEUROTOXIC RECREATIONAL DRUGS AND A METHOD OF TREATING RECREATIONAL DRUG ABUSE | STARGATE INTERNATIONAL LIMITED (NZ) | 2007-06-21 | — | — | WO | disclosed |
| US-20040005347-A1 | Composition comprising cocoa | N. V. NUTRICIA (NL) | 2004-01-08 | — | — | US | disclosed |
| EP-1370273-A1 | COMPOSITION COMPRISING COCOA AND A DOPAMINE D2 RECEPTOR AGONIST | N.V. Nutricia (NL) | 2003-12-17 | — | — | EP | disclosed |
| US-20020172732-A1 | Composition comprising cocoa | GENERAL NUTRITION INVESTMENT COMPANY | 2002-11-21 | — | — | US | disclosed |
| WO-2002074321-A1 | COMPOSITION COMPRISING COCOA AND A DOPAMINE D2 RECEPTOR AGONIST | N.V. NUTRICIA (NL) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | PDE9A, PDE3A, PDE2A | ADRA1A 177/4885FYN 3215/4885DRD2 123/4885 |
| US-20260049109-A1 | NOVEL IMMUNOMODULATORY, NEUROMODULATORY, OSTEOGENIC, AND ANTI-OSTEOPOROTIC HKUOT-S2 PROTEIN THAT ENHANCES BONE FRACTURE REPAIRS AND SUPPRESSES OSTEOPOROSIS DEVELOPMENT | SOST, IRF3, BMP2 | ADRA1A 3362/4885FYN 2914/4885DRD2 4610/4885 |
| US-20110224263-A1 | Cyclic pyridyl-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals | PPARD, PPARG, PPARA | ADRA1A 451/4885FYN 2183/4885DRD2 1887/4885 |
| US-20260135486-A1 | RIPPLE SUPPRESSION IN MULTI-PHASE BUCK CONVERTERS | DSP, RIPK1, DNER | ADRA1A 4178/4885FYN 3745/4885DRD2 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.